Artificial Intelligence (AI) is revolutionising various industries, and pharmaceutical manufacturing is no exception. While much attention has been given to AI’s role in accelerating drug discovery, its impact on process development for large-scale drug manufacturing is equally transformative. Dr James Dalton, from KPMG’s R&D Tax Incentives Practice, explores how AI can enhance the efficiency, reliability, and scalability of drug production processes, along with future trends and regulatory adaptations.
AI has the potential to reshape large-scale pharmaceutical manufacturing by optimising production processes, improving quality control, and reducing costs. Through advanced data analytics and machine learning, AI can monitor equipment performance in real time, predict maintenance needs, and adjust variables like temperature or pressure to maintain consistent product quality.
It also enables faster identification of production bottlenecks and enhances supply chain efficiency by forecasting demand and managing inventory. These capabilities not only streamline operations but also ensure that medicines are produced more reliably and at scale, helping meet global healthcare demands more effectively.
Optimising Process Design and Scale-Up
One of the critical challenges in drug manufacturing is optimising process design and scaling up from laboratory to industrial production. AI models, particularly machine learning algorithms, can analyse vast amounts of process development data to identify optimal processing parameters quickly.
This reduces development time and minimises waste, ensuring a more efficient transition from small-scale to large-scale production. For example, AI can simulate various process conditions to determine the best combination of temperature, pressure, and reactant concentrations for maximum yield. This allows manufacturers to scale up production with confidence, knowing the process parameters are optimised for efficiency and quality.
Advanced Process Control (APC)
AI-driven Advanced Process Control (APC) systems could become pivotal in maintaining the desired output quality during manufacturing. By integrating real-time sensor data with AI algorithms, these systems could dynamically adjust process parameters to maintain optimal conditions. This not only enhances product quality but also reduces the likelihood of production errors and downtime.
For instance, in a bioreactor used for drug production, AI can continuously monitor variables such as pH, temperature, and nutrient levels. If any parameter deviates from the optimal range, the AI system can automatically adjust inputs to bring the process back to the desired state, ensuring consistent product quality.
This could be applied to all aspects of production, from raw material handling to packaging. This not only speeds up production but also ensures higher consistency and quality of the final product. AI systems can automatically adjust process parameters in real-time to maintain optimal conditions, reducing the likelihood of human error and improving overall efficiency.
Smart Monitoring and Maintenance
AI technologies enable smart monitoring and predictive maintenance of manufacturing equipment. By continuously analysing data from sensors embedded in machinery, AI can predict potential failures before they occur. This proactive approach minimises unplanned downtime and extends the lifespan of critical equipment, ensuring a more reliable manufacturing process.
For example, AI can analyse vibration patterns and temperature data from a centrifuge used in drug purification. If the data indicates an impending mechanical issue, the system can alert maintenance staff to perform preventive maintenance, avoiding costly breakdowns. This proactive approach minimises downtime and ensures a smoother production process. Pharmaceutical companies already use AI to automate visual inspections on production lines, significantly reducing the time and cost associated with manual inspections.
Continuous Improvement Through Trend Monitoring
AI excels at identifying patterns and trends in complex datasets. In drug manufacturing, AI can monitor production trends to identify areas for continuous improvement. By analysing historical and real-time data, AI systems can suggest process adjustments that enhance efficiency, reduce costs, and improve overall product quality. A potential use case could be the tracking of the performance of different batches of a drug and identify subtle variations in production conditions that lead to higher yields.
By implementing these insights, manufacturers can continuously refine their processes to achieve better results. This ensures that the production remains within specified parameters, leading to higher quality and compliance. For example, AI systems can continuously monitor critical quality attributes and process parameters, making real-time adjustments to maintain product quality.
Enhancing Supply Chain Resilience
AI’s ability to predict and respond to supply chain disruptions could play a significant role in large-scale drug manufacturing. By analysing data from various sources, AI could forecast potential supply chain issues and recommend strategies to mitigate them. This ensures a steady supply of raw materials and components, reducing the risk of production delays. For instance, AI can predict shortages of critical raw materials based on global supply chain data and suggest alternative suppliers or materials to ensure uninterrupted production.
Challenges
However, the integration of AI also presents challenges. There are concerns about hallucinations, data privacy and the need for robust cybersecurity measures to protect sensitive information.
One of the key risks of using AI in large-scale drug manufacturing is the potential for hallucinations, instances where AI generates false or misleading information that appears credible. In a manufacturing context, this could lead to incorrect process recommendations, flawed quality control insights, or inaccurate predictions about equipment performance. If not carefully validated, such outputs could compromise product safety, regulatory compliance, or operational efficiency.
To mitigate this, AI systems must be rigorously tested, continuously monitored, and always used alongside expert human oversight. A closed agent can help prevent AI hallucinations by operating within a tightly controlled environment that limits exposure to unreliable or irrelevant data. These systems are trained on curated, domain-specific datasets and follow strict operational rules, reducing the likelihood of generating false or speculative outputs.
By incorporating human-in-the-loop oversight, closed agents ensure that critical decisions are reviewed and validated by experts before implementation. Their actions are fully traceable and auditable, which is essential for compliance in regulated industries. Additionally, real-time monitoring and feedback mechanisms allow for immediate detection and correction of anomalies, further safeguarding against hallucinations and ensuring consistent, reliable performance.
The complexity of AI systems requires skilled personnel for implementation and maintenance, which can be a barrier for some companies. Furthermore, regulatory frameworks must evolve to keep pace with AI advancements, ensuring that AI applications meet safety and quality standards. Balancing these benefits and challenges is crucial for the successful adoption of AI in pharmaceutical manufacturing.
Investing in AI for large-scale drug manufacturing involves significant financial burdens, particularly in the early stages. Costs include acquiring high-performance computing infrastructure, integrating AI with existing manufacturing systems, and hiring or training specialised talent. Additionally, ongoing expenses for data management, model validation, cybersecurity, and regulatory compliance can be substantial. While the long-term benefits, such as improved efficiency and reduced waste, can offset these costs, the upfront investment can be a barrier for many organisations, especially those with limited R&D budgets.
R&D tax credits could play a crucial role in easing the financial burden of adopting AI in pharmaceutical manufacturing. Companies can claim a tax credit of 30% qualifying R&D expenditures. This incentive, combined with the standard 12.5% corporate tax deduction, can result in a net subsidy of over 40%.
For firms investing in AI infrastructure, data systems, and skilled personnel, these supports significantly reduce upfront costs and encourage long-term innovation within Ireland’s life sciences sector. Grants also have the potential to greatly reduce this burden. Additionally, significant grants are available for feasibility studies, RD&I activities, and training; these could also help ease the cost of a transition to AI.
Adapting Regulations to AI Trends in Drug Manufacturing
Regulatory agencies, such as the FDA, are developing risk-based frameworks to assess AI technologies used in drug manufacturing. These frameworks focus on evaluating the credibility and reliability of AI models to ensure they meet safety and quality standards.
They are also increasingly collaborating with industry stakeholders to understand the practical applications of AI and address potential challenges. This collaboration ensures that regulations are both effective and feasible for implementation.
Regulatory frameworks require significant updating to address ethical and safety concerns associated with AI. This includes ensuring non-discrimination, transparency, and accountability in AI applications. For instance, the European Medicines Agency (EMA) is focusing on creating guidelines that ensure AI technologies do not introduce biases or compromise patient safety.
AI enables real-time monitoring of manufacturing processes, which regulatory bodies can leverage to ensure compliance with quality standards. This continuous oversight helps maintain high standards throughout the production lifecycle.
As AI technologies are adopted globally, there is a push towards harmonising regulatory standards across different regions. This ensures consistency in the evaluation and approval of AI-driven manufacturing processes.
Conclusion
AI’s integration into the process development phase of drug manufacturing holds immense potential. From optimising process design and scale-up to enhancing supply chain resilience, AI-driven technologies are set to make drug manufacturing more efficient, reliable, and scalable. As the pharmaceutical industry continues to embrace AI, we can expect significant advancements in the production of high-quality drugs, ultimately benefiting patients worldwide. Regulatory bodies are actively adapting to these trends, ensuring that AI can be safely and effectively integrated into pharmaceutical production.
Failing to adopt AI could lead to significant competitive and operational disadvantages. Without AI-driven optimisation, companies may face higher production costs, slower response times to market demands, and increased risk of quality control issues compared to their competitors. Manual or outdated systems can also struggle to meet evolving regulatory standards and traceability requirements. Over time, this can erode market share, reduce profitability, and limit a company’s ability to innovate, especially as competitors leverage AI to streamline operations, reduce waste, and accelerate time-to-market.
For more insights or if you have an R&D-related query, visit KPMG’s R&D Incentives practice.
Guest post by Dr James Dalton, from KPMG’s R&D Tax Incentives Practice
